Introduction
Atherosclerotic cardiovascular disease (ASCVD), which includes coronary heart disease (CHD), peripheral vascular disease and stroke, is currently one of the most common causes of morbidity and mortality worldwide. 1 Unfortunately the prevalence of ASCVD is expected to increase further over the next few decades due to a number of factors including an ageing population and increasing industrialisation. The latter is associated with increased exposure to known ASCVD risk factors 2 In Hong Kong, the prevalence of ASCVD risk factors has increased markedly over the past few decades. For example, the [2005] [2006] [2007] [2008] Hong Kong Cardiovascular Risk Factor Prevalence Study-3 (CRISPS-3) reported an 8.6% increase in the prevalence of abdominal obesity (waist circumference ≥90 cm in men and ≥80 cm in women) and a 21.5%
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classified as having a low, moderate, or high risk of developing atherosclerotic cardiovascular disease, and appropriate interventions selected accordingly. Recommended lifestyle modifications include adopting a healthy eating pattern; maintaining a low body mass index; quitting smoking; and undertaking regular, moderate-intensity physical activity. Pharmacological interventions should be selected as appropriate after lifestyle modification. increase in the prevalence of hypertension among a cohort of 1803 subjects recruited from CRISPS-1, the first such survey conducted between 1995 and 1996. 3 Of the 551 participants of the Hong Kong Cardiovascular Task Force Risk Management Programme, 65.4% had hypertension, 63.7% dyslipidaemia, and 33.3% diabetes at baseline (BMY Cheung, unpublished data).
2016年香港預防動脈粥樣硬化性心血管疾病的 共識聲明
Global efforts are underway to promote ASCVD prevention and reduce the risk of major ASCVD events. These efforts have yielded benefitsbetween 1990 and 2013, a substantial reduction in cardiovascular mortality was seen in central Europe (5.2%) and western Europe (12.8%), attributed primarily to birth cohorts' decreased exposure to tobacco smoking, improvements in diet, improved treatment of cardiometabolic risk factors, and improved treatment of CVD. . 5 Prior to the consensus meetings, group members reviewed the 2008 Consensus Statement and relevant guidelines from the American College of Cardiology/American Heart Association, the European Society of Hypertension/European Society of Cardiology, and the Eighth Joint National Committee for the Management of High Blood Pressure, among others. [5] [6] [7] [8] [9] At the meetings, each topical recommendation of the 2008 Statement was assessed against the pooled recommendations on that topic from the international guidelines reviewed. A final recommendation on each topic was generated by consensus after discussion.
The recommendations included in this consensus statement constitute the consensus opinion of the members of the Hong Kong Cardiovascular Task Force regarding the most appropriate interventions for the Hong Kong population.
Recommendations

Risk assessment
Total cardiovascular risk
Total ASCVD risk is based on the complex interactions of a number of different risk factors that together have a multiplicative effect. That is, the risk of ASCVD is amplified to a greater extent by the interaction of multiple risk factors than would be expected due to the cumulative effect of each risk factor alone. 7, 9 The present standard of practice for the primary prevention of ASCVD is to determine a patient's total ASCVD risk using a formal risk scoring algorithm. 1, 7, 9 Who to assess?
In Hong Kong, it is recommended that ASCVD prevention efforts should be focused on adults aged 40 years or older who have at least one ASCVD risk factor. 1, 9 The total ASCVD risk should be formally calculated for such individuals, and they should receive ASCVD prevention advice and/or treatment according to their determined level of risk (high, moderate, or low). 1, 9 High-risk patients will benefit most from treatment and include:
• patients with overt ASCVD (CHD, previous myocardial infarction, previous stroke, or peripheral vascular disease) or those who are symptomatic (eg have experience with angina) • patients with diabetes mellitus • patients with one major ASCVD risk factor (eg moderate-to-severe hypertension, severely elevated lipid levels) 9 These patients automatically meet the threshold for intensive risk factor treatment and need not undergo formal risk scoring. 1, 9 How to assess?
It is important to note that the current recommendations do not espouse a preference for any particular method of risk projection, but recommend that formal ASCVD risk scoring should be performed for all potentially at-risk patients.
A patient's 10-year (total) risk for ASCVD may be calculated using a variety of methods. The most recently published algorithm uses the American Pooled Cohort Risk Assessment Equations that are sex-and race-specific estimates for African-American and White men and women aged 40 to 79 years. They utilise age, total and high-density lipoprotein (HDL) cholesterol, systolic blood pressure (BP), diabetes, and current smoking status to calculate the total ASCVD risk. 1 The European Systematic Coronary Risk Evaluation (SCORE) system is another wellvalidated system that uses sex, age, systolic BP, total cholesterol, and current smoking status to predict the risk of fatal cardiovascular events. 7 Another risk assessment system, QRISK2, includes the risk factor of 'self-assigned ethnicity' (including Chinese) in the computation 10, 11 ; however, the model was validated
for Chinese immigrants to the United Kingdom and, thus, its applicability to the local Chinese population is unknown. The calculated risk score is used to stratify patients into low-, moderate-, and high-risk categories (Fig) . When interpreting these scores, the clinician should bear in mind that they were developed and validated for western populations. In addition, it must be remembered that any calculated ASCVD score is simply an indicator of total cardiovascular risk. 9 Although it can guide patient treatment, it cannot be a substitute for individualised patient evaluation and management. The clinician is advised to take all factors into account and to treat the patient individually rather than treat the risk score.
Risk interventions
There is robust scientific evidence that the development of ASCVD in at-risk patients may be slowed and/or prevented by lifestyle modification, reduction of metabolic risk factors, and pharmacological treatment. 7, [9] [10] [11] [12] [13] [14] [15] [16] [17] [18] [19] and diabetes [20] [21] [22] treatment guidelines incorporate the latest evidence on how to treat these conditions and to what appropriate targets. The clinician is referred to these guidelines for further guidance.
Diet
Treatment goal: an overall healthy eating pattern
All patients at increased risk of ASCVD should be given advice and specific recommendations for eating a healthy diet. Advice should include 9 : • matching energy intake with energy needs;
• eating a variety of fruits, vegetables, grains, lowor non-fat dairy products, legumes, fish, poultry, and lean meats; • reducing saturated and trans fats to <10% of total daily caloric intake, through replacement with polyunsaturated fats (vegetables, nuts, seeds, and seafood); • reducing cholesterol intake; • reducing salt intake; and • limiting alcohol intake to no more than two drinks per day for men and one drink per day for women.
Physical activity
Treatment goal: a minimum of 30 minutes of moderate-intensity physical activity at least 5 times a week, or a minimum of 15 minutes of vigorousintensity physical activity at least 5 times a week 9
• 'Moderate intensity' is defined as exercising at 64% to 76% of maximum heart rate (ie 220 minus age); activities include brisk walking, slow cycling, vacuuming, gardening, golf, tennis (doubles), ballroom dancing, and water aerobics. 9 'Vigorous intensity' is defined as exercising at 77% to 93% of maximum heart rate; activities include race walking, jogging or running, bicycling, heavy gardening, swimming laps, and tennis (singles). 9 • The practice of the popular Chinese soft martial art tai chi may also be beneficial for individuals at risk of ASCVD. A systematic review has shown that tai chi has physiological and psychosocial benefits, and it also appears to be safe and effective in promoting flexibility, balance control, and cardiovascular fitness in older patients with chronic conditions.
23
• All patients should consult their doctor prior to initiating graded exercise programmes.
Overweight/obesity
Treatment goal: maintenance of normal body mass index and waist circumference
• Normal body mass index is 18.5-22.9 kg/m 2 for Asians, 24 and normal waist circumference is <90 cm (35.4 inches) for men and <80 cm (31.5 inches) for women. 25 • Patients who are overweight or obese should strive to achieve normal body weight by restricting caloric intake and increasing physical activity.
• Drug therapy or surgical interventions may be a helpful adjunct for the treatment of severe obesity in some patients.
Smoking
Treatment goal: complete smoking cessation [7] [8] [9] • Patients with a systolic BP of ≥130 mm Hg or diastolic BP of ≥80 mm Hg should be given advice and specific recommendations on reducing lifestyle risk factors.
• Patients who do not meet their primary goals as defined above should be given drug therapy tailored to their circumstances.
• The choice of first-line therapy is the prerogative of the attending physician. Suitable antihypertensive drugs include calcium channel blockers, angiotensin-converting enzyme (ACE) inhibitors, and angiotensin receptor blockers (ARBs), either alone or in combination (Tables  1 and 2 ). 7, 9 Diuretics (chlorthalidone and indapamide) and β-blockers may also be used, but their long-term use is associated with increased risk of new-onset diabetes 30, 31 ; of note, there is no evidence that hydrochlorothiazide-one of the most commonly prescribed antihypertensivesin its usual dose of 12.5 to 25 mg daily reduces myocardial infarction, stroke, or death. 32 • When target BP cannot be achieved with monotherapy or with a two-drug combination, doses can be increased; if target BP cannot be achieved by a two-drug combination at full doses, switching to another two-drug combination, or adding a third drug, may be considered. [7] [8] [9] In patients with uncontrolled BP despite treatment with maximally tolerated doses of three antihypertensive medications, addition of the aldosterone antagonist spironolactone has achieved larger reductions in systolic BP than addition of the β-blocker bisoprolol, the alphaadrenergic blocker doxazosin, or placebo. • Patients at low and moderate risk should be given advice and specific recommendations on lowering LDL-C through dietary adjustments, increased physical activity, and weight reduction. If the target is not met after 6 months, they should be given a lipid-lowering agent (Tables 4  and 5 ).
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• Patients at high risk should immediately be started on lipid-lowering therapy with a high-intensity statin (Tables 4 and 5) . 35 Importantly, however, pharmacokinetic studies have shown that Chinese patients achieve a higher plasma concentration of statin compared with Caucasians, and this may be associated with an increased risk of adverse effects. 36 Consequently, the maximum approved doses of the statins available in Asia are around half the maximum approved doses in the United States. 37 The clinician should, therefore, exercise caution when prescribing high-intensity statin therapy.
• Inhibitors of proprotein convertase subtilisin/ kexin type 9 have recently been approved for use Abbreviations: ACS = acute coronary syndrome; BP = blood pressure; CHD = coronary heart disease; CKD = chronic kidney disease; eGFR = estimated glomerular filtration rate; ESH-ESC = European Society of Hypertension/European Society of Cardiology; HF = heart failure; JNC 8 = Eighth Joint National Committee; NICE = National Institute for Health and Care Excellence Clinical trials have demonstrated decreases in LDL-C by up to 60% in subjects receiving these agents 38 ; definitive evidence of reduced cardiovascular event rates associated with their use may be provided by ongoing trials.
Diabetes
Risk factor treatment goal: glycated haemoglobin <7% [20] [21] [22] • All diabetic patients are considered high risk for the development of ASCVD 9, 21 and should receive appropriate management upon diagnosis. This includes guidance on diet modification and increased physical activity in conjunction with pharmacotherapy. [20] [21] [22] Early initiation of medication is recommended to avoid any delay in treatment. Insulin is administered if treatment goals are not achieved with oral therapy. [20] [21] [22] Treatment goal for glycaemia should be tailored according to the patient profile in order to avoid hypoglycaemia in those with co-morbidities or in elderly patients. 22, 40 • In diabetic patients, treat other ASCVD risk factors more aggressively, 22 including hypertension. Nevertheless, present evidence suggests that a BP target of <140/85 mm Hg is appropriate in patients with diabetes, with a lower Abbreviations: ACE = angiotensin-converting enzyme; AV = atrioventricular; COPD = chronic obstructive pulmonary disease; LV = left ventricular; MI = myocardial infarction in older patients or those with a long duration of diabetes, and the risk and benefit of intensive BP lowering needs to be considered individually according to the patient profile. BMY Cheung, unpublished data) . Similarly 64% of the diabetic patients were treated with metformin (68.8%) and/or gliptins (36%), while 78.1% of patients with dyslipidaemia were treated with a statin. Notably, however, treatment goals for hypertension (<130/80 mm Hg for diabetic patients, <140/90 mm Hg for non-diabetics) and diabetes (glycated haemoglobin <7%) were met by just over 50% of hypertensive patients and approximately 60% of diabetics.
Ensuring physician compliance with evidence-based guidelines and improving clinician understanding of factors affecting patient compliance with treatment may be the key to decreasing ASCVD risk in the Hong Kong population.
Differences between the 2008 and 2016 consensus statements
The present update of the 2008 Consensus Statement introduces the use of the new American Pooled Cohort Risk Assessment Equations that have superseded the Framingham Risk Evaluation; ASCVD risk can be assessed using either these equations or the European SCORE system to stratify patients into low-, moderate-, or high-risk categories to aid targeting of therapies as well as the establishment of suitable treatment goals. The risk factor reduction goals for hypertension and dyslipidaemia have been updated to reflect the most current recommendations from the Eighth Joint National Committee, the European guidelines on the management of arterial hypertension, and the European guidelines on cardiovascular disease prevention in clinical practice. The HDL-C target included in the 2008 Consensus Statement has been omitted from the current update as increased HDL-C has not been proven to reduce ASCVD risk.
Conclusions
The development of ASCVD in at-risk patients may be slowed and/or prevented by lifestyle modification, reduction of metabolic risk factors, and pharmacological treatment. The clinician plays a central role in ASCVD prevention-identifying at-risk patients, calculating the total ASVCD risk score, encouraging lifestyle changes, and providing targeted interventions to achieve specific treatment goals. Nonetheless, it is vital that the clinician is not overly focused on the treatment of isolated ASCVD risk factors but should instead adopt a 'wholeperson' approach to diagnosis and therapy. Many patients present with multiple risk factors and, therefore, individualised, nuanced patient evaluation and management is essential to achieve optimum outcomes. Finally, none of these interventions will result in ASVCD prevention without the cooperation of the patient. Clinicians are encouraged to build strong partnerships with their patients, with the aim of establishing individual ownership of their treatment plans and, thus, improved treatment compliance.
